drugset / Trial / NCT00973245
BAY59-7939 in Atrial Fibrillation Once Daily (OD)
RandomizedParallel-groupOpen-labelPrevention
Summary
This is an exploratory investigation of safety, pharmacokinetic (PK) and pharmacodynamic (PD) effects of BAY59-7939 with multiple oral doses of 10 mg, 15 mg and 20 mg once daily (od) in Japanese subjects with non-valvular atrial fibrillation (originally described in Japanese).
Timeline
- Start
- 2006-07
- Primary completion
- —
- Completion
- 2007-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivaroxaban | Other / unclassified | 10 mg | Oral |
| Subject | Rivaroxaban | Other / unclassified | 15 mg | Oral |
| Subject | Rivaroxaban | Other / unclassified | 20 mg | Oral |
| Comparator | Warfarin | Small molecule | — | — |